An Innovative Canadian Pharmaceutical Company

7 Products To Be Launched In 2021 / 2022 ($45M. Estimated Peak Sales / Year)

Sponsored
Message: CLIENT FEATURE: Valeo Pharma (VPH: CSE) An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline

CLIENT FEATURE: Valeo Pharma (VPH: CSE) An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline

posted on Jan 13, 2021 10:32AM

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases, ¬†Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Click below to read in its entirety.

 FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.
Share
New Message
Please login to post a reply